Editas Medicine, Inc. (EDIT) Social Stream
Editas Medicine Inc (EDIT) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering EDIT.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
EDIT's average price target has moved up $6.32 over the prior 22 months.
Over the past 47 weeks, EDIT's average upside potential has been 43.49%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
EDIT Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
Over the past 21 months, EDIT's average broker recommendation rating worsened by 0.28.
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- To contextualize these metrics, consider that out of all US stocks, Editas Medicine Inc's variance in analysts' estimates is lower than -751.65% of them.
- Editas Medicine Inc's number of analysts covering the stock is greater than 817% of stocks in the mid market cap category.
- To contextualize these metrics, consider that out of stocks in the mid market cap category, Editas Medicine Inc's upside potential (average analyst target price relative to current price) is higher than 783.3% of them.
- In terms of how Editas Medicine Inc fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 611.1% of that group.
Make investment decisions regarding EDIT using the data that counts. Try POWR Ratings for free.